More and more anxiety and depression after colorectal cancer are related to these factors

Share This Post

In a study published online on April 6 in Cancer, the prevalence of depression and anxiety increased among patients with colorectal cancer (CRC).

The team of Dr. Floortje Mols from the University of Tilburg in the Netherlands examined the symptoms of depression and anxiety in patients with CRC. Between 2000 and 2013, 2,625 patients diagnosed with CRC completed the Hospital Anxiety and Depression Scale and the European Cancer Quality of Life Questionnaire, which included a sample of 315 individuals with age and gender matching specifications.

The researchers found that patients reported significantly higher prevalence of depression (19% vs 12.8%) and anxiety disorder (20.9% vs 11.8%) compared to the standard sample. The longer the diagnosis of cancer, the more the depression symptoms are reduced; the older men are less likely to be anxious, but they are more prone to depression; the married patients’ anxiety and depression are reduced; the lower the education level, the more comorbid diseases, the more anxiety and depression. Severe anxiety and depression symptoms are associated with lower global quality of life, physical condition, role, cognition, mood, and social function.

Therefore, screening and referral are the most important, especially for those who are single, have low education, and have many comorbidities.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy